High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Disease

Interventions

BIOLOGICAL: NewGam

Sponsor

Octapharma